Pennsylvania has a chance to update its law to allow for biosimilar medicine substitutions

Share with others:


Print Email Read Later

As a physician, I have seen the difference biologic medicines have made for patients suffering from skin disease, cancer, multiple sclerosis and rheumatoid arthritis. Treatment with biologics is extending and improving lives and providing a way to manage diseases like never before. Equally good news is that on the horizon are biosimilars, or “copies,” that are highly similar, although not exact, versions of the original biologic. This is worthy news for patients because it will make safe and presumably lower-cost alternatives readily available.

While the U.S. Food and Drug Administration will make scientific decisions on whether to approve a biologic, including whether it is so similar as to be deemed interchangeable with the original product, it is state law that determines under what circumstances an interchangeable biosimilar may be substituted.

The Pennsylvania Senate recently passed legislation that would update pharmacy laws and establish the necessary treatment of the substitution of biosimilars. Physicians would maintain the right to make sure their patients receive the best treatment, while pharmacists would be able to provide lower-cost alternatives. Timely communication between the pharmacist and the physician would be fostered to maintain complete and accurate medical records. In addition, a robust system of reporting, tracking and tracing any adverse events also would maintain patient safety and hold manufacturers responsible for their products.

I call upon the Pennsylvania House of Representatives to take the necessary steps to facilitate Pennsylvanians’ access to biosimilar medicines through appropriate substitution policies.

MARK P. SERALY, M.D.
Peters


Join the conversation:

Commenting policy | How to report abuse
To report inappropriate comments, abuse and/or repeat offenders, please send an email to socialmedia@post-gazette.com and include a link to the article and a copy of the comment. Your report will be reviewed in a timely manner. Thank you.
Commenting policy | How to report abuse

Advertisement
Advertisement
Advertisement

You have 2 remaining free articles this month

Try unlimited digital access

If you are an existing subscriber,
link your account for free access. Start here

You’ve reached the limit of free articles this month.

To continue unlimited reading

If you are an existing subscriber,
link your account for free access. Start here